Myasthenia gravis is an autoimmune disease. The immune system produces antibodies that attack the communication points between nerves and muscles, causing muscle weakness that worsens with activity and improves with rest. Around 116,000 people in the United States live with the condition.
How the Immune System Causes Muscle Weakness
Muscles move when nerves release a chemical messenger called acetylcholine. That messenger crosses a tiny gap and lands on receptor sites on muscle cells, triggering contraction. In myasthenia gravis, the immune system produces antibodies that destroy or block those receptor sites. With fewer sites available, the muscles receive weaker signals from the nerves, and strength drops.
About 85% of people with myasthenia gravis have antibodies targeting acetylcholine receptors directly. Another 6% have antibodies aimed at a different protein called MuSK, which helps form strong connections between nerves and muscles. A smaller group has antibodies against a protein called LRP4, which plays a similar structural role. When any of these proteins are blocked, the signal between nerve and muscle is limited or fails entirely. A small percentage of patients test negative for all known antibodies, a situation called “seronegative” myasthenia gravis, though the underlying process is still considered autoimmune.
The Role of the Thymus Gland
The thymus, a small organ behind the breastbone, is central to the autoimmune process in myasthenia gravis. It normally trains immune cells during childhood and then shrinks in adulthood. In people with MG, the thymus often stays enlarged or develops abnormal growths, and it becomes the primary site where the immune system generates the rogue cells and antibodies that attack the neuromuscular junction.
About 80% of people with acetylcholine receptor antibody-positive MG have thymic abnormalities. Thymic enlargement (hyperplasia) appears in 50% to 60% of early-onset cases. Between 10% and 30% of MG patients have a thymoma, a tumor of the thymus that is usually slow-growing and most common in men over 50. Surgical removal of the thymus is a well-established treatment option that can reduce symptom severity or lead to remission in some patients.
What the Symptoms Look Like
The hallmark of myasthenia gravis is weakness that gets worse with repeated use of a muscle and improves after rest. It commonly starts in the eyes: drooping eyelids and double vision are the first symptoms for many people. About 15% of patients will only ever have these eye-related symptoms, a form called ocular myasthenia gravis.
For the other 85%, weakness spreads to other parts of the body within about three years, usually affecting the face, neck, arms, or legs. Chewing may become tiring partway through a meal. Speech can turn nasal or slurred after talking for a while. Lifting your arms overhead or climbing stairs might feel disproportionately exhausting. This broader pattern is called generalized myasthenia gravis. In the most serious cases, weakness affects the muscles used for breathing, a medical emergency known as myasthenic crisis. People who experience myasthenic crisis have a significantly higher long-term mortality risk compared to those who do not.
How It Is Diagnosed
A blood test for acetylcholine receptor antibodies is often the first step. This test is highly specific, meaning a positive result almost certainly confirms MG. It picks up the condition in 88% to 93% of people with generalized disease, though only about 50% to 71% with the ocular form. If this test comes back negative, a blood test for MuSK antibodies is typically the next step and catches roughly half of the remaining cases.
When blood tests are inconclusive, nerve and muscle testing can help. Repetitive nerve stimulation, where small electrical pulses are sent to a nerve while muscle response is measured, shows characteristic patterns in 50% to 70% of generalized MG cases. Single-fiber electromyography is more sensitive: it detects abnormalities in up to 99% of generalized cases when two muscles are tested, and approaches 100% sensitivity for ocular MG when the right facial muscle is examined.
Treatment Approaches
Because myasthenia gravis is autoimmune, treatment focuses on controlling the immune response and improving nerve-to-muscle signaling. Traditional options include medications that slow the breakdown of acetylcholine (giving it more time to activate remaining receptors), drugs that broadly suppress the immune system, and thymus removal surgery.
Newer therapies target the autoimmune process more precisely. One class works by lowering the levels of harmful antibodies in the bloodstream. These treatments block a recycling mechanism that normally keeps antibodies circulating longer. They are given as infusions over several weeks and can produce noticeable improvement within that timeframe. Another class blocks part of the immune system’s attack machinery, called complement proteins, which would otherwise destroy healthy tissue at the neuromuscular junction. Both approaches are approved for generalized MG in patients with acetylcholine receptor antibodies and represent a shift toward more targeted treatment with fewer of the broad side effects associated with traditional immune suppression.
Who Gets Myasthenia Gravis
MG can develop at any age, but it follows a pattern. In younger adults, it affects women more often. In older adults, men are diagnosed more frequently. The incidence in the U.S. is roughly 5 new cases per 100,000 people per year. It is not inherited in a simple genetic pattern, but having a family member with an autoimmune condition does slightly increase risk, consistent with the way autoimmune diseases tend to cluster in families. People with MG are also more likely to have other autoimmune conditions, such as thyroid disease or rheumatoid arthritis, which further underscores its autoimmune nature.